Table 3 |
|||
|
Adverse events reported during the study |
|||
|
Body system |
Normal/mild |
Moderate/severe |
Total |
|
|
|||
|
Any event |
2 (20%) |
11 (37%)* |
13 (33%) |
|
Cardiovascular |
|||
|
Any event |
0 |
4 (13%) |
4 (10%) |
|
Cardiac arrest |
0 |
2 (7%) |
2 (5%) |
|
Sinus arrest |
0 |
1 (3%) |
1 (3%) |
|
Ventricular fibrillation |
0 |
1 (3%) |
1 (3%) |
|
Digestive |
|||
|
Any event |
1 (10%) |
3 (10%) |
4 (10%) |
|
Diarrhoea |
1 (10%) |
1 (3%) |
2 (5%) |
|
Ileus |
0 |
2 (7%) |
2 (5%) |
|
Ischaemic bowel |
0 |
1 (3%) |
1 (3%) |
|
Body as a whole |
|||
|
Any event |
0 |
3 (10%) |
3 (8%) |
|
Multiple organ failure |
0 |
2 (7%) |
2 (5%) |
|
Sepsis |
0 |
1 (3%) |
1 (3%) |
|
Musculoskeletal |
|||
|
Any event |
0 |
2 (7%) |
2 (5%) |
|
Muscle rigidity |
0 |
2 (7%) |
2 (5%) |
|
Nervous |
|||
|
Any event |
1 (10%) |
1 (3%) |
2 (5%) |
|
Agitation |
1 (10%) |
1 (3%) |
2 (5%) |
|
|
|||
|
*P = 0.451 versus normal/mild group (Fisher's exact test). |
|||
|
Breen et al. Critical Care 2004 8:R21 doi:10.1186/cc2399 |
|||